 

# FOR IMMEDIATE RELEASE

Tuesday, November 3, 2015 Media Contact:

Kaity Dunn, Rasor Marketing Communications

513-­‐793-­‐1234 (office) or 317-­‐379-­‐9601 (cell); kaity@rasormarketing.com

**Global Medical Device Provider AtriCure Celebrates Ribbon Cutting and Grand Opening of New Headquarters in the City of Mason**

*Biohealth Cluster expands with 94,000-­‐square-­‐foot headquarters in City of Mason’s Oak Park District*

(Mason, OH – November 3, 2015) On Tuesday, November 3, City of Mason and AtriCure leadership celebrated the ribbon cutting and grand opening of the medical device company’s new 94,000-­‐square-­‐foot headquarters. The 10.5 acre site is located in Mason’s Oak Park District on Innovation Way near Western Row and I-­‐71. The company is relocating over 200 employees from its current headquarters in West Chester.

Several community members attended the event. In addition, AtriCure employees were bussed from their current location in West Chester to attend the event and were able to tour the building.

“Our new headquarters will give us the platform to grow our employee base, and to continue to make innovative progress in the fields of research, design and product manufacturing for the surgical treatment of atrial fibrillation,” said Michael Carrel, President and CEO of AtriCure, “And we couldn’t have chosen a better place to build. The ecosystem of companies here in the Oak Park district offers a dynamic environment, in addition to the City of Mason’s focus on a strong culture of wellness.”

The City of Mason’s biohealth corridor in the new Oak Park District on Innovation Way is envisioned to be a walkable district featuring dining, open creative spaces and retail to appeal to the City’s growing millennial workforce. AtriCure joins other businesses in the Oak Park District such as Luxottica’s EyeMed, Stress Engineering’s Medical Device Division, the Lindner Center of HOPE and Seapine Software. In addition, Assurex Health has chosen Oak Park for its new 60,000 square-­‐foot headquarters.

“AtriCure is making innovative strides in their industry and attracting young, creative talent along the way. It’s an honor to have them in the Oak Park District,” said City of Mason Mayor David F. Nichols. “This ribbon-­‐cutting event is a significant mile-­‐marker in our journey of building a leading hub of businesses in the biohealth sector.”

“Medical device manufacturing is a growing segment of our regional economy," said Johnna Reeder, president & CEO of REDI Cincinnati. "We’re pleased that AtriCure is committed to Greater Cincinnati. We look forward to seeing the company continue to grow here in the region.”

# About the City of Mason, Ohio

Mason, Ohio is an established hub for bioscience innovation and includes a business portfolio of advanced manufacturing, healthcare and technology companies. As the largest city in Warren County and part of the Greater Cincinnati region in southwest Ohio, Mason’s economic development mission is focused on attracting and supporting the growth of top companies and creating jobs in these sectors, while leveraging partnerships to also attract foreign

direct investment. Ranked the seventh best place to live by CNN/Money Magazine in 2013 and 17th in 2015, Mason is nationally recognized for its low cost of living, award-­‐winning schools and its intentional culture of wellness. For more information, visit: WhyMason.com.

# About AtriCure

AtriCure, Inc. is a medical device company providing innovative atrial fibrillation (Afib) solutions designed to produce superior outcomes that reduce the economic and social burden of atrial fibrillation. AtriCure’s Synergy™ Ablation System is the first and only surgical device approved for the treatment of persistent and longstanding persistent forms of Afib in patients undergoing certain open concomitant procedures. AtriCure’s AtriClip left atrial appendage management (LAAM) exclusion device is the most widely sold device worldwide that’s indicated for the occlusion of the left atrial appendage. The company believes cardiothoracic surgeons are adopting its ablation and LAAM devices for the treatment of Afib and reduction of Afib related complications such as stroke. Afib affects more than 33 million people worldwide. For more information visit AtriCure.com or follow us on Twitter @AtriCure.

###